"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
This pre-release, containing insights from executives across leading African upstream, downstream, financing, and service providers, spotlights developments in local capabilities, infrastructure, and new projects that are driving change in some of Africa's most interesting oil and gas producing countries.